Ioannis Economou MD

Gastroenterology•Glenview, IL

Inflammatory Bowel Disease, Clinical Pharmacology

Director, Inflammatory Bowel Disease Program

Join to View Full Profile

2150 Pfingsten RdGlenview, IL 60026
Phone+1 847-657-1900
Fax+1 847-733-5041

Education & Training

Rutgers Health/Robert Wood Johnson Medical SchoolFellowship, Gastroenterology, 2006 - 2009
Cleveland Clinic FoundationFellowship, Inflammatory Bowel Disease, 2005 - 2006
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2003 - 2005
Washington University/B-JH/SLCH ConsortiumInternship, Internal Medicine, 2002 - 2003
Ruprecht Karl University Faculty of MedicineClass of 1999

Certifications & Licensure

IL State Medical License 2017 - 2026
NY State Medical License 2015 - 2025
NJ State Medical License 2006 - 2023
CT State Medical License 2009 - 2015
OH State Medical License 2005 - 2006
American Board of Internal Medicine Gastroenterology

Clinical Trials

Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis Start of enrollment: 2015 Jun 17
Completed
Phase 3
Efficacy of Alicaforsen in Pouchitis Patients Who Have Failed to Respond to at Least One Course of Antibiotics Start of enrollment: 2015 Dec 03
Completed
Phase 3
A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis Start of enrollment: 2016 Jan 13
Completed
Phase 1
Entyvio (Vedolizumab) Long Term Safety Study Start of enrollment: 2015 Mar 24
COMPLETED
A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease Start of enrollment: 2016 May 18
Active, not recruiting
Phase 2
Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease Start of enrollment: 2016 Aug 25
COMPLETED
PHASE2
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) Start of enrollment: 2017 Jan 31
ACTIVE_NOT_RECRUITING
PHASE3
Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease Start of enrollment: 2018 Feb 27
TERMINATED
PHASE3
Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year Start of enrollment: 2018 Mar 29
COMPLETED
PHASE3
Join now to see all

Publications & Presentations

PubMed

9 citations
Visceral Adiposity Independently Predicts Time to Flare in Inflammatory Bowel Disease but Body Mass Index Does Not.
Priya Sehgal, Steven Su, John Zech, Yael Nobel, Lyndon Luk
Inflammatory Bowel Diseases. 2024-04-03
1 citations
Acute Pancreatitis with Colonic Pseudo-obstruction in a Patient with COVID-19.
Jeremy Van, Jason Kramer, Ioannis Economou
Case Reports in Gastroenterology. 2022-03-01
46 citations
Human Placenta-derived Cells (PDA-001) for the Treatment of Moderate-to-severe Crohn's Disease: A Phase 1b/2a Study.
Gil Y. Melmed, William M. Pandak, Kevin Casey, Bincy Abraham, John F. Valentine
Inflammatory Bowel Diseases. 2015-08-01

Press Mentions

Lifestyle Factors May Help Prevent Many Inflammatory Bowel Disease CasesDecember 21st, 2022

Professional Memberships

American Gastroenterological Association - AGA
Member
American College of Gastroenterology - ACG
Member
CCFA
Member
European Crohn's and Colitis Organisation
Member

Other Languages

German, Greek

External Links

Profilehttps://www.northshore.org/apps/findadoctor/physicians/ioannis-economou